ISIS 3521 is an antisense compound that binds to an mRNA sequence specific to PKC-alpha and thus selectively inhibits production of this protein without inhibiting production of other proteins in the PKC family. Using antisense technology it is possible to selectively inhibit a single family member that may play a role in disease while allowing other members of the family to continue to perform normal cellular functions. This high degree of specificity may provide antisense drugs substantial advantage over traditional small molecule drugs in many difficult to treat diseases. According to the American Cancer Society, lung cancer is the leading cause of cancer death for both men and women. This year, approximately 169,500 new cases of lung cancer will be diagnosed and 157,400 Americans will die due to the disease.
More people die of lung cancer than of colon, breast and prostate cancers combined.
A replay of the webcast will be available at this address for up to 90 days. Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs. In addition, Isis has 11 products in its development pipeline, with two in late-stage development and four in Phase II human clinical trials. Isis is preparing to initiate a Phase III program for ISIS 2302, an ICAM-1 inhibitor, in Crohn's disease. Isis has a broad and proprietary patent estate of nearly 700 issued and allowed patents worldwide.